Bicoll GmbH Receives First Payment as Member of the €11.5 Million EU Funded Epimirna Project to Develop Novel Epilepsy Therapeutics
10/29/2013 9:01:20 AM
Munich (Germany) – October 29th, 2013 – BICOLL Group announces today to receive the first
payment as participant and work package leader in the EpimiRNA consortium. Recently the whole
consortium was granted up to €11.5 Million funding by the European Union over the next five years.
BICOLL is responsible for the consortium’s small molecule drug discovery program and drive this
first-ever large-scale approach in epilepsy research with its effective technology of fractionated plant
extracts. BICOLL’s Profiles™ technology evidentially leads to the identification of potent small
molecules as ligands with an unprecedented rapidity. In parallel the unique technology enables rapid
and reliable in vivo target validation studies for the to-be established screening systems. BICOLL is
also tasked to support the consortium with its medicinal chemistry competence once small molecules
The causes for epilepsy are not yet sufficiently understood and treatments remain deficient while over
50 million people across the world suffer from this most common serious neurological disorder. Recent
discoveries have identified a new type of molecule in cells called microRNA, which may be critical to
controlling the changes in brain chemistry that accompany the development and course of epilepsy.
The EpimiRNA consortium, initiated by BICOLL, represents a major interdisciplinary effort involving
16 partners from 8 European countries, the USA and Brazil to uncover the complete spectrum of
effects of microRNA in epilepsy. Epilepsy researchers, geneticists, clinicians, experts in advanced
molecular sciences and research-active life sciences companies will work together to understand
molecular mechanisms and develop diagnostics as well as novel small molecule therapeutics.
“BICOLL's plant Profiles™ just recently proved their effectiveness again1, and we are very excited to
see plant Profiles™ now applied in the emerging area of microRNA manipulation”, comments Dr. Kai
Lamottke, managing director of BICOLL. “Driving the consortium’s small molecule drug approach we
are able to include associated partners from pharmaceutical and biotech industry to the EpimiRNA
consortium. We are now looking for such partners, who want to secure access to the consortium's
findings early on and broaden the impact of their as well of the consortium’s research”.
The project is funded by the European Union's ‘Seventh Framework’ Programme (FP7/
http://cordis.europa.eu/fp7/home_en.html) under grant agreement n°602130 from September 2013 to
August 2018 and coordinated by Professor David Henshall, Royal College of Surgeons in Ireland with
Professor Felix Rosenow at Philipps University Marburg (Germany) as co-coordinator. For a more
detailed description of the project see: www.epimirna.eu .
BICOLL is a biopharmaceutical company, offering pre-clinical support in the area of Drug Discovery from Natural
Products and Medicinal Chemistry. Dedicated to the discovery and optimization of the highest quality lead compounds,
BICOLL provides an efficient, multi-disciplinary approach to drug discovery. With outstanding expertise in high tech
natural product chemistry and validated experience in medicinal chemistry, BICOLL increases quality and quantity of the
drug discovery pipeline of its partner's candidates portfolio.
The BICOLL Group provides its services to a number of international clients of various fields of interest, e.g.
pharmaceutical and agrochemical industry. The BICOLL Group comprises two legal entities: BICOLL GmbH in Munich,
Germany and BICOLL Biotechnology (Shanghai) Co. Ltd., P.R. China. Technology development, cooperation
management and marketing are functions in Munich, while facilities for research and development are located in Shanghai.
BICOLL currently employs 40 people at both locations.
Dr. Nicole Feling, Public Relations Management
+49 (0) 89 / 82010630,
Help employers find you! Check out all the jobs and post your resume.
comments powered by